5 Biotech Stocks to Steer Clear of as Trump Vows to Lower Drug Prices

For those who thought that the pharma/biotech sector is in for an extraordinary run after Donald Trump’s unexpected victory, his latest vow to crack down on excessive drug price hikes comes as a bolt from the blue.

This year has been fraught with headwinds for the pharma/biotech sector. Global efforts toward health care cost containment created pricing pressure on drugs and market access.

Back to news